FOR YOUR PATIENTS WITH UPPER GI CANCER BRING MORE LIFE TO THE TABLE
etapidi Product Profile
etapidi (tislelizumab) is a monoclonal antibody targeting the programmed death-1 (PD-1) receptor on immune cells, including T cells. By blocking PD-1 signaling, etapidi helps restore T-cell activity and supports the immune response against cancer cells.
etapidi is indicated in adults for the treatment of:
- Metastatic non-small cell lung cancer (NSCLC)
- Metastatic NSCLC
- Advanced or metastatic esophageal squamous cell carcinoma (ESCC)
- Nasopharyngeal carcinoma (NPC)
Active Ingredients:
Tislelizumab is an Fc-engineered humanized immunoglobulin G4 (IgG4) variant monoclonal antibody produced in recombinant Chinese hamster ovary cells.
Excipients:
Trisodium citrate dihydrate, Citric acid monohydrate, L histidine hydrochloride monohydrate, L-histidine, Trehalose dihydrate, polysorbate-20 (E432), and Water for injections.
1L, first line; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; GEJC, gastroesophageal junction cancer; GI, gastrointestinal; Squamous NSCLC, Squamous cell non-small cell lung cancer;Non-Squamous NSCLC, Non-Squamous cell non-small cell lung cancer; OS, overall survival.